Anti cancer activity of rodent tuber (Thyphonium flagelliforme (lodd.) Blume on human breast cancer t47d cells

International Journal of Phytomedicine

Volumn 3, Issue 1, 2011, Pages 138-146

  Nurrochmad, Arief ^a   Lukitaningsih, Endang ^a   Meiyanto, Edy ^a  

^a GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Anti cancer; Chemoprevention; Rodent tuber (Thyphonium flagelliforme (Lodd.) Blume); T47D cells

Indexed keywords

ANTINEOPLASTIC AGENT; PLANT EXTRACT; TAMOXIFEN; THYPHONIUM FLAGELLIFORME EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACEAE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MONOTHERAPY; THYPHONIUM FLAGELLIFORME;

EID: 79960335977     PISSN: None     EISSN: 09750185     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Singletary K, MacDonald C, Lovinelli M, Fisher C, Wallig M. Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene, Carcinogenesis. 1998;9(6):1039-1043.
2. Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchrest BA. Telomeric DNA induces apoptosis and senescence of human carcinoma cells, Breast Cancer Research. 2007;9:R13.
3. Choo CY, Chan KL, Sam TW, Hitotsuyanagi Y, Takeya K. The cytotoxicity and chemical constituents of the hexane fraction of Thyponium flagelliformae (Araceace). J Ethnopharmacol. 2001;77:129-131.
4. Lai CS, Mas RH, Nair NK, Majid MI, Mansor SM, Navaratnam V. Thyponium flagelliformae inhibits cancer cell growth in vitro and induced apoptosis: an evaluation by the bioactivity guided approach. J. Ethnopharmacol. 2008;118:14-20.
5. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun. 1991;179:661-667.
6. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer. 1994;30A(11):1675-1682.
7. Hsieh CY, Santell RC, Haslam SZ and Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833-3838.
8. Shao ZM, Shen ZZ, Fontana JA, Barsky SH. Genistein's "ER-dependent and independent" actions are mediated through ER pathways in ER-positive breast carcinoma cell lines. Anticancer Res. 2000;20:2409-2416.
9. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer. 1997;27:31-40.
10. Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett. 1998;130:143-152.
11. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360:817-824.
12. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98-101.
13. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women. Lancet. 1998;352:93-97.
14. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet.2003;361:296-300.
15. Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids, Environ Health Perspect 1998;106:807-812.
16. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five vs more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptorpositive tumors. J. Natl Cancer Inst. 1996;88:1529-1542.
17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.